CLINICAL_TRIALS
trial_result
· 2017-03-01
Clinical Trial Update: Effect of the Aquaretic Tolvaptan on Nitric Oxide System [Phase 2]
Summary
A Phase 2 trial evaluating tolvaptan's effect on the nitric oxide system in autosomal dominant polycystic kidney disease has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regional Hospital Holstebro | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: COMPLETED